Open Access

Effect of procalcitonin on the prognosis of patients with COPD

  • Authors:
    • Chen Gong
    • Ying Yang
    • Minli Chen
    • Zhengfu Xie
  • View Affiliations

  • Published online on: April 22, 2020     https://doi.org/10.3892/br.2020.1298
  • Pages: 313-318
  • Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the effect of procalcitonin levels on the prognosis of chronic obstructive pulmonary disease (COPD), and its relationship with other indices of infection. Inpatients diagnosed with acute aggravation of COPD between January 2017 and June 2018 were enrolled in the present study. Troponin, C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, percentage of neutrophils (NE%), hospitalization days and hospitalization expenses were collected and followed up for half a year to observe the survival rate in patients with COPD and the risk of acute aggravation. There were 246 patients with procalcitonin (PCT) levels <0.1 ng/ml, among whom 55 were randomly selected and assigned to a PCT negative group; and another 55 patients with PCT levels ≥0.1 ng/ml were assigned to a PCT positive group. The serum CRP, ESR, WBC count, NE% and hospitalization expenses in the PCT positive group were significantly higher compared with the PCT negative group (P<0.05). There was a positive association between PCT levels and CRP, WBC, NE% and hospitalization expenses, but not between PCT and ESR. The number of AECOPD events occurring within half a year between the two groups was statistically significant (χ²=5.923; P<0.05), and there was no significant correlation between PCT and recurrence frequency. Together, the results of the present study suggest that the levels of PCT in patients with acute aggravation may reflect the severity of COPD and may be used as a reference value for prognostic risk assessment. Serum PCT levels may be used as an indicator to predict duration and cost of hospitalization.
View References

Related Articles

Journal Cover

June-2020
Volume 12 Issue 6

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gong C, Yang Y, Chen M and Xie Z: Effect of procalcitonin on the prognosis of patients with COPD. Biomed Rep 12: 313-318, 2020
APA
Gong, C., Yang, Y., Chen, M., & Xie, Z. (2020). Effect of procalcitonin on the prognosis of patients with COPD. Biomedical Reports, 12, 313-318. https://doi.org/10.3892/br.2020.1298
MLA
Gong, C., Yang, Y., Chen, M., Xie, Z."Effect of procalcitonin on the prognosis of patients with COPD". Biomedical Reports 12.6 (2020): 313-318.
Chicago
Gong, C., Yang, Y., Chen, M., Xie, Z."Effect of procalcitonin on the prognosis of patients with COPD". Biomedical Reports 12, no. 6 (2020): 313-318. https://doi.org/10.3892/br.2020.1298